SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Curaxis Pharmaceutical Corp – IPO: ‘S-1/A’ on 10/28/05 – EX-5.1

On:  Friday, 10/28/05, at 4:11pm ET   ·   Accession #:  1193125-5-211097   ·   File #:  333-128193

Previous ‘S-1’:  ‘S-1/A’ on 10/13/05   ·   Next:  ‘S-1/A’ on 11/10/05   ·   Latest:  ‘S-1/A’ on 12/8/05

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

10/28/05  Curaxis Pharmaceutical Corp       S-1/A                  5:1.7M                                   RR Donnelley/FA

Initial Public Offering (IPO):  Pre-Effective Amendment to Registration Statement (General Form)   —   Form S-1
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: S-1/A       Amendment No. 2 to Form S-1                         HTML   1.21M 
 2: EX-3.3      Second Amendment and Restated Certificate of        HTML     48K 
                          Incorporation                                          
 3: EX-4.1      Specimen Stock Certificate                          HTML     16K 
 4: EX-5.1      Opinion of Wilmer Cutler Pickering Hale and Dorr    HTML     13K 
                          LLP                                                    
 5: EX-23.1     Consent of Pricewaterhousecoopers LLP               HTML      6K 


EX-5.1   —   Opinion of Wilmer Cutler Pickering Hale and Dorr LLP


This exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



  OPINION OF WILMER CUTLER PICKERING HALE AND DORR LLP  

Exhibit 5.1

 

LOGO

 

LOGO

October 28, 2005

 

Voyager Pharmaceutical Corporation

8540 Colonnade Center Drive

Raleigh, North Carolina 27615

 

Re: Registration Statement on Form S-1

 

Ladies and Gentlemen:

 

This opinion is furnished to you in connection with a Registration Statement on Form S-1 (File No. 333-128193) (the “Registration Statement”) filed with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”), for the registration of 6,785,000 shares of Common Stock, $0.001 par value per share (the “Shares”), of Voyager Pharmaceutical Corporation, a Delaware corporation (the “Company”), including 885,000 Shares issuable upon exercise of an over-allotment option by granted the Company.

 

The Shares are to be sold by the Company pursuant to an underwriting agreement (the Underwriting Agreement) to be entered into by and between the Company and W.R. Hambrecht + Co., LLC, the form of which has been filed as Exhibit 1.1 to the Registration Statement.

 

We are acting as counsel for the Company in connection with the issue and sale by the Company of the Shares. We have examined signed copies of the Registration Statement as filed with the Commission. We have also examined and relied upon the Underwriting Agreement, minutes of meetings of the stockholders and the Board of Directors of the Company as provided to us by the Company, stock record books of the Company as provided to us by the Company, the Certificate of Incorporation and By-Laws of the Company, each as restated and/or amended to date, and such other documents as we have deemed necessary for purposes of rendering the opinions hereinafter set forth.

 

In our examination of the foregoing documents, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as copies, the authenticity of the originals of such latter documents and the legal competence of all signatories to such documents.

 

We express no opinion herein as to the laws of any state or jurisdiction other than the state laws of the Commonwealth of Massachusetts, the General Corporation Law of the State of Delaware and the federal laws of the United States of America.

 

 

LOGO


Voyager Pharmaceutical Corporation

October 28, 2005

Page 2

 

 

Based upon and subject to the foregoing, we are of the opinion that the Shares have been duly authorized for issuance and, when the Shares are issued and paid for in accordance with the terms and conditions of the Underwriting Agreement, the Shares will be validly issued, fully paid and nonassessable.

 

Please note that we are opining only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters. This opinion is based upon currently existing statutes, rules, regulations and judicial decisions, and we disclaim any obligation to advise you of any change in any of these sources of law or subsequent legal or factual developments which might affect any matters or opinions set forth herein.

 

We hereby consent to the filing of this opinion with the Commission as an exhibit to the Registration Statement in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act and to the use of our name therein and in the related Prospectus under the caption “Legal Matters.” In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission.

 

Very truly yours,

 

WILMER CUTLER PICKERING

HALE AND DORR LLP

By:   /s/ John B. Watkins
    John B. Watkins, a Partner

Dates Referenced Herein

This ‘S-1/A’ Filing    Date    Other Filings
Filed on:10/28/05None on these Dates
 List all Filings 
Top
Filing Submission 0001193125-05-211097   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sat., May 11, 9:12:17.1pm ET